NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System
News provided by
Share this article
LOS ANGELES, Jan. 22, 2021 /PRNewswire/ --
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders, announces that the Centers for Medicare & Medicaid Services ("CMS") is establishing two new Level II Healthcare Common Procedure Coding System ("HCPCS") codes for the
Monarch eTNS System®, effective April 1, 2021, as part of the final coding decisions of its
. The new codes are K1016 (Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve) and K1017 (Monthly supplies for use of device coded at K1016). Securing these codes is an important milestone in enabling payer coverage and payment decisions.